Reuters logo
BRIEF-Amgen says second phase 3 study shows kyprolis regimen significantly improves overall survival in patients with relapsed multiple myeloma
2017年7月12日 / 晚上8点17分 / 4 个月前

BRIEF-Amgen says second phase 3 study shows kyprolis regimen significantly improves overall survival in patients with relapsed multiple myeloma

July 12 (Reuters) - Amgen Inc

* Second phase 3 study shows Kyprolis (carfilzomib) regimen significantly improves overall survival in patients with relapsed multiple myeloma

* Amgen Inc - adverse events observed in updated analysis were consistent with those previously reported for Aspire

* Amgen Inc - study met key secondary endpoint

* Amgen Inc - ‍patients treated with Kyprolis-based regimen survived 7.9 months longer than patients on Lenalidomide and Dexamethasone​

* Amgen Inc - ‍Kyprolis, Lenalidomide and Dexamethasone reduced risk of death by 21 percent versus Lenalidomide and Dexamethasone​ Source text for Eikon: Further company coverage:

我们的标准:汤森路透“信任原则”
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below